Internal Medicine, Hematology & Oncology · Cincinnati, OH
NPI
1366722787
Since 2011
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
4460 Red Bank Rd, Suite 200
Cincinnati, OH, 45227
Phone (513) 321-4333
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.8M
75,671 services
Medicare patients, 2024
290
Average age 75
Drug cost, 2024
$3.1M
938 prescriptions
Company payments, 2025
$507
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Weiping Zang was code J1439 (injection, ferric carboxymaltose, 1 mg), 23,250 times for 15 patients. In total Weiping Zang billed 75,671 services in 97 codes, and Medicare paid $1.8M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-10-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 23,250 | 15 | $0.88 | $20K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 756 | 21 | $0.09 | $66.77 |
| 85025 Blood Count | Office | 287 | 101 | $7.54 | $2,163 |
| 96375 Injection Administration | Office | 255 | 31 | $10.94 | $2,789 |
| 99214 Office E&M - Established | Office | 228 | 103 | $90.53 | $21K |
| 96413 Chemotherapy Administration | Office | 201 | 35 | $91.10 | $18K |
| 80053 Clinical Chemistry | Office | 138 | 32 | $10.35 | $1,428 |
| 96372 Injection Administration | Office | 103 | 39 | $10.04 | $1,034 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 100 | 21 | $0.63 | $63.11 |
| 96365 Intravenous Infusion, Hydration | Office | 98 | 32 | $43.27 | $4,241 |
| 99215 Office E&M - Established | Office | 92 | 36 | $130.15 | $12K |
| 96367 Intravenous Infusion, Hydration | Office | 75 | 18 | $20.45 | $1,534 |
| 99233 Hospital E&M - Subsequent | Facility | 60 | 31 | $89.84 | $5,390 |
| J7030 Infusion, normal saline solution , 1000 cc | Office | 56 | 25 | $2.00 | $112 |
| 96360 Intravenous Infusion, Hydration | Office | 56 | 26 | $23.27 | $1,303 |
By year: 2022 $1.5M for 84,721 services; 2023 $1.1M for 68,314 services; 2024 $1.8M for 75,671 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 287 | 101 | $7.54 | $2,163 |
| 80053 Clinical Chemistry | 138 | 32 | $10.35 | $1,428 |
Medicare prescription drug claims, 2024
In 2024, the drug Weiping Zang prescribed most often to Medicare patients was Anastrozole, with 102 prescriptions and refills. In total Weiping Zang wrote 938 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 102 | 262 | 25 | $1,798 |
| Eliquis Apixaban | 81 | 177 | 21 | $104K |
| Allopurinol Generic | 34 | 94 | 14 | $294 |
| Hydroxyurea Generic | 34 | 93 | 12 | $967 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 31 | 31 | Under 11 | $1,011 |
| Revlimid Lenalidomide | 30 | 30 | Under 11 | $696K |
| Potassium Chloride Generic | 28 | 59 | 15 | $1,094 |
| Jakafi Ruxolitinib Phosphate | 23 | 23 | Under 11 | $400K |
| Calquence Acalabrutinib Maleate | 23 | 23 | Under 11 | $356K |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 23 | 23 | 14 | $302 |
| Oxycodone Hcl Generic | 22 | 22 | Under 11 | $290 |
| Acyclovir Generic | 22 | 53 | Under 11 | $543 |
| Lenalidomide Generic | 19 | 19 | Under 11 | $273K |
| Letrozole Generic | 17 | 35 | Under 11 | $145 |
| Promethazine Hcl Generic | 16 | 16 | 11 | $172 |
Brand drugs: 253 claims; generic drugs: 685 claims; opioid claims: 64.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Weiping Zang $507 ($507 in general payments such as food, travel and fees) from 6 companies. The largest payer was Boston Scientific Corporation with $164.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.